Baader Bank Aktiengesellschaft Sells 3,300 Shares of GeneDx Holdings Corp. (NASDAQ:WGS)

Baader Bank Aktiengesellschaft lessened its holdings in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 33.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 6,700 shares of the company's stock after selling 3,300 shares during the quarter. Baader Bank Aktiengesellschaft's holdings in GeneDx were worth $515,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Fred Alger Management LLC bought a new position in GeneDx in the third quarter valued at about $16,731,000. Geode Capital Management LLC raised its holdings in GeneDx by 8.7% in the 3rd quarter. Geode Capital Management LLC now owns 377,631 shares of the company's stock valued at $16,030,000 after buying an additional 30,379 shares during the last quarter. State Street Corp boosted its position in GeneDx by 18.3% during the 3rd quarter. State Street Corp now owns 314,914 shares of the company's stock worth $13,365,000 after buying an additional 48,735 shares during the period. Millennium Management LLC boosted its position in GeneDx by 193.5% during the 2nd quarter. Millennium Management LLC now owns 311,401 shares of the company's stock worth $8,140,000 after buying an additional 205,318 shares during the period. Finally, Zweig DiMenna Associates LLC bought a new stake in GeneDx during the 4th quarter worth approximately $23,788,000. Institutional investors own 61.72% of the company's stock.

Wall Street Analysts Forecast Growth

WGS has been the topic of a number of recent research reports. Craig Hallum lifted their price target on shares of GeneDx from $70.00 to $95.00 and gave the stock a "buy" rating in a report on Wednesday, October 30th. Wells Fargo & Company lifted their target price on GeneDx from $34.00 to $75.00 and gave the stock an "equal weight" rating in a report on Wednesday, October 30th. TD Cowen increased their price target on GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a research note on Tuesday, January 7th. Finally, The Goldman Sachs Group lifted their price objective on GeneDx from $54.00 to $70.00 and gave the stock a "neutral" rating in a research note on Wednesday, October 30th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, GeneDx presently has a consensus rating of "Moderate Buy" and a consensus target price of $70.67.

Insider Buying and Selling at GeneDx

In other news, CEO Katherine Stueland sold 23,108 shares of the company's stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $70.48, for a total transaction of $1,628,651.84. Following the transaction, the chief executive officer now directly owns 82,318 shares of the company's stock, valued at $5,801,772.64. This represents a 21.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder School Of Medicine At Mo Icahn sold 20,359 shares of GeneDx stock in a transaction on Friday, November 15th. The shares were sold at an average price of $69.78, for a total transaction of $1,420,651.02. Following the completion of the sale, the insider now directly owns 2,846,474 shares of the company's stock, valued at approximately $198,626,955.72. The trade was a 0.71 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 363,669 shares of company stock valued at $28,061,081. 27.30% of the stock is currently owned by company insiders.

GeneDx Trading Down 6.3 %

Shares of NASDAQ:WGS traded down $4.74 during midday trading on Monday, reaching $70.11. The company's stock had a trading volume of 514,893 shares, compared to its average volume of 847,417. GeneDx Holdings Corp. has a fifty-two week low of $3.63 and a fifty-two week high of $98.87. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40. The firm has a 50 day moving average price of $78.29 and a two-hundred day moving average price of $58.33. The firm has a market capitalization of $1.93 billion, a price-to-earnings ratio of -22.85 and a beta of 2.01.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.